Last update 23 Aug 2025

PEG-Loxenatide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
PEG loxenatide, pegloxenatide, Polyethylene Glycol Loxenatide
+ [4]
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (05 May 2019),
RegulationPriority Review (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
China
05 May 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesPhase 1
China
07 Jul 2015
NephrosisPhase 1
China
07 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Pubmed
ManualManual
Not Applicable
12,341
rjvuinezzz(bxbvoetykn) = whthqopnrb hixjjtnknn (qtbneiirpo )
Positive
13 Feb 2025
incretin glucose-lowering agents
rjvuinezzz(bxbvoetykn) = zyycokgfek hixjjtnknn (qtbneiirpo )
Phase 4
156
PEG-Loxe 0.3 mg
qogzgybiyp(aednvflask) = wxdvrkxthf ygzsqcwaua (flonnkjpwk )
-
01 Jan 2023
Metformin 1500 mg
qogzgybiyp(aednvflask) = jdtsoymxtb ygzsqcwaua (flonnkjpwk )
Phase 1
23
nfsqfgflzi(svahlqltdn) = rzwntgxbnm crglsbktnw (nxeyaonjrt )
Positive
01 Dec 2019
Phase 3
533
Metformin+Placebo
xsfmentheh(javqrrynib) = The gastrointestinal reactions were mild during the entire study rwigxjvqwm (dxhdbhqtyo )
Positive
19 Sep 2019
Metformin+PEX168 100 µg
Phase 3
406
ftxhynxold(greetqlgqq) = No serious adverse events (SAEs) occurred in each group during the trial qrleamntab (txbrlsibim )
Positive
17 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free